Full Breakdown
Retraction of Glyphosate Safety Study Raises Ethical Concerns
12/9/2025, 9:14:54 PM
Overview of the Retraction
A significant scientific paper published in 2000, which asserted that glyphosate, the active ingredient in the herbicide Roundup, "does not pose a health risk to humans," has been formally retracted due to serious ethical concerns regarding its authorship. The retraction, announced in November 2025, follows revelations that employees of Monsanto, the company that developed Roundup, acted as undisclosed ghostwriters for the study. This paper, authored by Gary Williams, Robert Kroes, and Ian Munro, has been highly influential, cited in over 800 academic works and government documents.
Ethical Issues and Ghostwriting
The retraction notice, issued by Martin van den Berg, co-editor-in-chief of the journal *Regulatory Toxicology and Pharmacology*, highlights critical ethical issues that undermine the integrity of the paper. The involvement of Monsanto staff in drafting the article was not disclosed, raising questions about the independence of the authors and the validity of the conclusions drawn. The study relied heavily on unpublished data from Monsanto while omitting significant long-term studies that were available at the time. Van den Berg noted that the lack of transparency regarding financial compensation and authorship compromises the article's credibility.
Background on Glyphosate and Roundup
Glyphosate was first introduced by Monsanto in 1974 and has since become one of the most widely used herbicides globally. Its use surged with the advent of genetically modified crops, known as 'Roundup Ready' crops, which are engineered to withstand glyphosate application. Despite its popularity, glyphosate has been the subject of intense scrutiny, particularly following a 2015 classification by the World Health Organization's International Agency for Research on Cancer, which deemed it "probably carcinogenic to humans."
Ongoing Controversy and Legal Implications
The retraction of the 2000 study adds weight to ongoing debates about glyphosate's safety. Bayer, which acquired Monsanto in 2018, has faced significant legal challenges, including over 67,000 lawsuits alleging that Roundup causes cancer. The company has already paid approximately $10 billion in settlements related to these claims. Critics, including environmental charities and scientists, continue to call for independent research to assess the potential health risks associated with glyphosate.
Official Statements and Responses
In response to the retraction, Bayer stated that Monsanto's involvement in the paper did not equate to authorship and was disclosed in the acknowledgments. The company maintains that the authors had full control over the manuscript. Van den Berg emphasized that the retraction does not imply a stance on glyphosate's carcinogenicity but is a necessary action to uphold publication ethics.
Conflicting Reports and Gaps
While the retraction has been widely reported, there remains a lack of consensus on glyphosate's safety. The U.S. Environmental Protection Agency is currently updating its evaluation of glyphosate's carcinogenic potential, following challenges to its previous assessments. This ongoing uncertainty highlights the need for rigorous, independent research to clarify the health implications of glyphosate exposure.
Verbatim Quotes
- “The failure to disclose the involvement of Monsanto personnel in the writing process compromises the academic independence of the presented findings and conclusions drawn in the article regarding carcinogenicity.” — Martin van den Berg, Co-editor-in-chief, *Regulatory Toxicology and Pharmacology*.
- “In a statement, it said, “Monsanto’s involvement with the Williams et al paper did not rise to the level of authorship and was appropriately disclosed in the acknowledgments.” — Bayer spokesperson.
The retraction of this pivotal study underscores the complexities surrounding glyphosate and the ethical responsibilities of scientific research, leaving the debate over its safety far from resolved.
